ID: ALA4876289

Max Phase: Preclinical

Molecular Formula: C17H19N3O4S

Molecular Weight: 361.42

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COc1ncc(C2=CCOCC2)cc1S(=O)(=O)Nc1ccnc(C)c1

Standard InChI:  InChI=1S/C17H19N3O4S/c1-12-9-15(3-6-18-12)20-25(21,22)16-10-14(11-19-17(16)23-2)13-4-7-24-8-5-13/h3-4,6,9-11H,5,7-8H2,1-2H3,(H,18,20)

Standard InChI Key:  MQQOMKBMLHBDFG-UHFFFAOYSA-N

Associated Targets(Human)

PI3-kinase p110-delta/p85-alpha 1508 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-alpha/p85-alpha 2589 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3K p110 beta/p85 alpha 919 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-gamma subunit 5411 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-delta subunit 6699 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serum albumin 2651 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 361.42Molecular Weight (Monoisotopic): 361.1096AlogP: 2.40#Rotatable Bonds: 5
Polar Surface Area: 90.41Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.21CX Basic pKa: 6.52CX LogP: 0.16CX LogD: 0.12
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.88Np Likeness Score: -1.05

References

1. Down K, Amour A, Anderson NA, Barton N, Campos S, Cannons EP, Clissold C, Convery MA, Coward JJ, Doyle K, Duempelfeld B, Edwards CD, Goldsmith MD, Krause J, Mallett DN, McGonagle GA, Patel VK, Rowedder J, Rowland P, Sharpe A, Sriskantharajah S, Thomas DA, Thomson DW, Uddin S, Hamblin JN, Hessel EM..  (2021)  Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.,  64  (18.0): [PMID:34510892] [10.1021/acs.jmedchem.1c01102]

Source